Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI

ClinicalTrials.gov ID: NCT03474029

Public ClinicalTrials.gov record NCT03474029. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 8, 2026, 10:42 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Six Weeks of Daily Rifapentine vs. a Comparator Arm of 12-16 Week Rifamycin-based Treatment of Latent M. Tuberculosis Infection: Assessment of Safety, Tolerability and Effectiveness

Study identification

NCT ID: NCT03474029
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 2, Phase 3
Lead sponsor: Centers for Disease Control and Prevention; Federal
Enrollment: 3,400 participants

Conditions and interventions

Conditions

Latent Tuberculosis

Interventions

Rifampin and Isoniazid daily for 12 weeks Drug
Rifampin daily for 16 weeks Drug
Rifapentine and Isoniazid weekly for 12 weeks Drug
Rifapentine daily for 6 weeks Drug

Drug

Eligibility (public fields only)

Age range: Not listed
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jul 31, 2019
Primary completion: Dec 30, 2029
Completion: Dec 30, 2029
Last update posted: May 5, 2026

2019 – 2029

United States locations

U.S. sites: 7
U.S. states: 5
U.S. cities: 6

Facility	City	State	ZIP	Site status
Denver Health and Hospital Authority	Denver	Colorado	80204	Recruiting
George Washington University	Washington D.C.	District of Columbia	20001	Recruiting
Washington DC VA Medical Center	Washington D.C.	District of Columbia	20001	Recruiting
New York Harbor Healthcare System	Manhattan	New York	10001	Recruiting
New York City Bureau of TB Control	New York	New York	11201	Recruiting
San Antonio VA	San Antonio	Texas	78201	Active, not recruiting
Seattle King County Health Department	Seattle	Washington	98101	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT03474029, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 5, 2026 · Synced May 8, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03474029 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →